Emerging biotechnologies, strategic collaborations, and growing focus on personalized and regenerative medicine are accelerating the next wave of gene therapy innovation.Austin, Nov. 05, 2025 (GLOBE ...
An increasing demand for gene therapies is focusing the industry on enhancing production capabilities, transitioning from ...
This article examines key innovations driving scalable, high-yield purification of recombinant AAVs and how they’re helping ...
There are a number of considerations that can help streamline the pathway to the clinic. One of the first is which vector ...
Lexeo Therapeutics, Inc. surges after FDA trial alignment for LX2006 in Friedreich’s ataxia. Click for more on LXEO stock ...
Contract development and manufacturing organization (CDMO) Matica Biotechnology has partnered with Calidi Biotherapeutics to advance and manufacture CLD-401, a tumor-tropic oncolytic virus designed to ...
Data demonstrates sustained clinical improvements in pain, stiffness and function for up to 156 weeks following a single ...
About OXB OXB (LSE: OXB) is a global quality and innovation-led contract development and manufacturing organisation (CDMO) in cell and gene therapy with a mission to enable its clients to deliver life ...
A patient dosed in the MAGNITUDE study has suffered a Grade 4 liver transaminases and increased total bilirubin.
SparingVision has dosed the first patient in its NYRVANA clinical trial of SPVN20 in patients with advanced retinitis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback